HCV and the Kidney: Let Bygones Be Bygones

November 18, 2016 | 02:00 PM - 04:00 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

Add to Outlook Calendar Add to Google Calendar Add to Yahoo! Calendar Add to iCal Calendar

Clinical Practice Session

HCV and the Kidney: Let Bygones Be Bygones

November 18, 2016 | 02:00 PM - 04:00 PM

Location: W375A

Session Description

This session focuses on the current state-of-the-art curative treatment of hepatitis C virus (HCV) infection in patients with kidney diseases. The presentations include the mechanisms and efficacy of the emerging anti-HCV drugs, optimal drug regimens in patients with renal failure, the renal pathology of HCV infection, and the impact of the new drugs on kidney transplantation.

Session Objectives

Upon completion of this session, the participant will be able to: 1. describe mechanisms of action of new anti-HCV drugs; 2. explain the efficacy of new anti-HCV drugs; 3. discuss the kidney pathology related to HCV; 4. apply the best therapeutic strategies for treatment of patients with HCV and renal diseases; and 5. describe the impact of the new anti-HCV drugs in renal transplantation and dialysis.

Learning Pathways

  • Chronic Kidney Disease
  • Pathology

Moderators

  • Thomas D. Nolin, PhD, PharmD, FASN
  • Michael J. Ross, MD, FASN

Lectures

Mechanisms and Efficacy of Emerging Anti-HCV Drugs Add to your Outlook, Google, Yahoo, or Apple iCal Calendar
02:00 PM - 02:30 PM
Raymond T. Chung, MD

HCV-Related Kidney Pathology Add to your Outlook, Google, Yahoo, or Apple iCal Calendar
02:30 PM - 03:00 PM
Erika R. Bracamonte, MD

Impact of New Anti-HCV Drugs on Renal and Liver Transplantation Add to your Outlook, Google, Yahoo, or Apple iCal Calendar
03:00 PM - 03:30 PM
Roy D. Bloom, MD

Optimal Treatment of Patients with HCV and Renal Diseased Add to your Outlook, Google, Yahoo, or Apple iCal Calendar
03:30 PM - 04:00 PM
David Roth, MD